Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients

by Lee, H.S., Fan, L., Khoo, Y.M., Goh, B.C., Wang, L., Lim, R., Ong, A.B., Chua, C.
Published 2012

Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients

by Lee, H.S., Goh, B.C., Fan, L., Khoo, Y.M., Wang, L., Lim, R., Ong, A.B., Chua, C.
Published 2014

Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma

by Chuah, B., Lim, R., Boyer, M., Ong, A.-B., Wong, S.-W., Kong, H.-L., Millward, M., Clarke, S., Goh, B.-C.
Published 2016

Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug

by Tham, L.-S., Lee, H.-S., Wang, L., Yong, W.-P., Fan, L., Ong, A.-B., Sukri, N., Soo, R., Lee, S.-C., Goh, B.-C.
Published 2014

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

by Goh, B.-C., Lee, S.-C., Wang, L.-Z., Fan, L., Guo, J.-Y., Lamba, J., Schuetz, E., Lim, R., Lim, H.-L., Ong, A.-B., Lee, H.-S.
Published 2014

A comparative study of dynamic contrast-enhanced MRI parameters as biomarkers for anti-angiogenic drug therapy

by Koh, T.S., Thng, C.H., Hartono, S., Tai, B.C., Rumpel, H., Ong, A.B., Sukri, N., Soo, R.A., Wong, C.I., Low, A.S.C., Humerickhouse, R.A., Goh, B.C.
Published 2014